Froehlich Janice C, Fischer Stephen M, Nicholson Emily R, Dilley Julian E, Filosa Nicholas J, Smith Teal N, Rademacher Logan C
Indiana University School of Medicine , Indianapolis, Indiana.
Mayo Clinic , Rochester, Minnesota.
Alcohol Clin Exp Res. 2017 Mar;41(3):644-652. doi: 10.1111/acer.13326. Epub 2017 Feb 9.
This study examined whether naltrexone (NTX) or varenicline (VAR), alone or in combination, can retard the phenotypic expression of a genetic predisposition toward high alcohol drinking in rats selectively bred for high alcohol intake when drug treatment is initiated prior to, or concomitantly with, the onset of alcohol drinking.
Alcohol-naïve P rats were treated daily with NTX (15.0 mg/kg BW), VAR (1.0 mg/kg BW), a combination of NTX (15.0 mg/kg BW) + VAR (1.0 mg/kg BW), or vehicle (VEH) for 2 weeks prior to, or concomitantly with, their first opportunity to drink alcohol and throughout 21 days of daily 2-hour alcohol access. Drug treatment was then discontinued for 3 weeks followed by reinstatement of drug treatment for an additional 3 weeks.
When P rats were pretreated with drug for 2 weeks prior to onset of alcohol access, only NTX + VAR in combination blocked the acquisition of alcohol drinking in alcohol-naïve P rats. When drug treatment was initiated concomitantly with the first opportunity to drink alcohol, NTX alone, VAR alone, and NTX + VAR blocked the acquisition of alcohol drinking. Following termination of drug treatment, NTX + VAR and VAR alone continued to reduce alcohol drinking but by the end of 3 weeks without drug treatment, alcohol intake in all groups was comparable to that seen in the vehicle-treated group as the expression of a genetic predisposition toward high alcohol drinking emerged in the drug-free P rats. After 3 weeks without drug treatment, reinstatement of NTX + VAR treatment again reduced alcohol intake.
A combination of NTX + VAR, when administered prior to, or concomitantly with, the first opportunity to drink alcohol, blocks the acquisition of alcohol drinking during both initial access to alcohol and during a later period of alcohol access in P rats with a genetic predisposition toward high alcohol intake. The results suggest that NTX + VAR may be effective in curtailing alcohol drinking in individuals at high genetic risk of developing alcoholism.
本研究考察了纳曲酮(NTX)或伐尼克兰(VAR)单独使用或联合使用时,在酒精摄入开始前或同时开始药物治疗的情况下,能否延缓选择性培育的高酒精摄入量大鼠中高酒精饮用遗传易感性的表型表达。
在无酒精经验的P大鼠首次有机会饮酒前2周或同时,每天用NTX(15.0毫克/千克体重)、VAR(1.0毫克/千克体重)、NTX(15.0毫克/千克体重)+VAR(1.0毫克/千克体重)组合或赋形剂(VEH)进行治疗,持续2周,并在每天2小时的酒精摄入期间持续21天。然后停药3周,随后再次恢复药物治疗3周。
当P大鼠在酒精摄入开始前2周用药物预处理时,只有NTX+VAR组合能阻止无酒精经验的P大鼠获得酒精饮用行为。当药物治疗与首次饮酒机会同时开始时,单独使用NTX、单独使用VAR以及NTX+VAR均能阻止酒精饮用行为的获得。药物治疗终止后,NTX+VAR和单独使用VAR继续减少酒精饮用,但在停药3周结束时,所有组的酒精摄入量与赋形剂治疗组相当,因为在无药物的P大鼠中出现了高酒精饮用的遗传易感性表达。在停药3周后,恢复NTX+VAR治疗再次减少了酒精摄入量。
NTX+VAR组合在首次饮酒机会前或同时给药时,在有高酒精摄入遗传易感性的P大鼠初次接触酒精期间和后期酒精接触期间,均能阻止酒精饮用行为的获得。结果表明,NTX+VAR可能对减少具有高酒精成瘾遗传风险个体的酒精饮用有效。